IMV.TO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Apr 2023 @ 03:59):

Stats
今日成交量	15 761.00
平均成交量	13 812.00
市值	13.12M
EPS	$0 ( 2024-03-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.183
ATR14	$0.0920 (8.21%)

音量相关性

長: -0.07 (neutral)

短: 0.00 (neutral)

Signal:(60.815) Neutral

IMV Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

IMV Inc 相关性 - 货币/商品

0.00
( neutral )

-0.41
( neutral )

0.16
( neutral )

0.62
( weak )

-0.30
( neutral )

-0.88
( strong negative )

IMV Inc 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-4.43

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-4.43

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0737

FY	2020
营收:	$3 000.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.0702

Financial Reports:

No articles found.

IMV Inc

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.